Zacks Investment ResearchFri, 19 Jun 2026 16:31:17 GMTImmunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?IMVT+1.59%
Zacks Investment ResearchFri, 12 Jun 2026 15:11:00 GMTImmunovant Stock Gains 12.4% in a Month: What's Driving It?IMVT+1.59%
Seeking AlphaMon, 25 May 2026 10:27:31 GMTImmunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad PotentialIMVT+1.59%
BenzingaThu, 21 May 2026 16:07:14 GMTThese Analysts Increase Their Forecasts On Immunovant After Q4 ResultsIMVT+1.59%
Zacks Investment ResearchThu, 21 May 2026 14:20:56 GMTIMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study DataIMVT+1.59%
BenzingaWed, 20 May 2026 17:09:06 GMTImmunovant Stock Surges Despite Disappointing Earnings MissIMVT+1.59%
Zacks Investment ResearchMon, 06 Apr 2026 18:10:38 GMTIMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study EndpointsIMVT+1.59%
Seeking AlphaThu, 02 Apr 2026 20:32:03 GMTImmunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update TranscriptIMVT+1.59%
